The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.a

Left or biventricular dysfunction/failure

Publications

Santos LG, Roque R, Antunes Santos R, Neves C, Bonito N

Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma.

Cureus. 2025;17(1):e76993

Mortara L, Pera G, Monti E, Morbelli S, Minuto F, Sambuceti G, Giusti M

Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.

Journal of endocrinological investigation. 2014;37(11):1099-108

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(32):5204-12